NeoVascularX is led by a team of experienced professionals with a passion for developing innovative solutions for AMD. Our team includes leading professors, researchers, and clinicians who are dedicated to advancing the field of ophthalmology and improving patient outcomes.
o nAMD (neovascular Age-related Macular Degeneration) is an advanced form of age-related macular degeneration (AMD) that can cause rapid and severe vision loss. nAMD involves the uncontrolled growth of new blood vessels in the back of the eye. Inhibition of neovascularization in the back of the eye has been proven to improve its symptoms.
Every year, around 200,000 people are diagnosed with nAMD in North America (Maguire MG. 2012)
In 2019, 18.3 million people over the age of 40 in the US were living with early-stage AMD and 1.5 million were living with late-stage AMD (Rein DB, et al., 2022)
Currently, all interventions approved by the FDA are injections to the eye. Failure to consistently inject leads to vision loss.
There are no topical products approved for nAMD.